US-based Conatus Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its drug candidate emricasan to treat liver transplant recipients with re-established fibrosis to delay the progression to cirrhosis and end-stage liver disease.

Emricasan is an orally active caspase protease inhibitor that is being developed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis) and treat patients with chronic liver disease and significant unmet medical need.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Conatus co-founder, president and chief executive officer Stephen Mento said: “This designation is a significant step forward for Conatus’s clinical development programme for emricasan.”

“This designation is a significant step forward for Conatus’s clinical development programme for emricasan.”

So far, emricasan has been studied in more than 500 subjects in ten clinical trials.

In a randomised Phase IIb clinical trial, emricasan showed statistically significant, consistent, rapid and sustained reduction in elevated levels of two major biomarkers of inflammation and cell death that are implicated in the severity and progression of liver disease.

The drug is currently in a Phase IIb trial in patients with acute-on-chronic liver failure (ACLF), as well as a Phase II clinical trial in patients with severe alcoholic hepatitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s initial development strategy targets patients with ACLF, chronic liver failure (CLF), and patients who have developed liver fibrosis postorthotopic liver transplant due to Hepatitis C virus infection.

Conatus expects to carry out further trials in 2014.